share_log

Stephens Lowers Lifecore Biomedical (NASDAQ:LFCR) to Equal Weight

Stephens Lowers Lifecore Biomedical (NASDAQ:LFCR) to Equal Weight

斯蒂芬斯将Lifecore Biomedical(纳斯达克股票代码:LFCR)的权重
Financial News Live ·  2023/03/24 14:52

Stephens downgraded shares of Lifecore Biomedical (NASDAQ:LFCR – Get Rating) from an overweight rating to an equal weight rating in a research note issued to investors on Monday, The Fly reports.

斯蒂芬斯下调了股票的评级 Lifecore Biomedical(纳斯达克:LFCR — 获取评级) The Fly报道,从周一发布给投资者的研究报告中的增持评级到同等权重评级。

Separately, Barrington Research reduced their price target on shares of Lifecore Biomedical from $12.00 to $10.00 in a research report on Wednesday, January 11th.

另外,巴灵顿研究公司在1月11日星期三的一份研究报告中将Lifecore Biomedicare股票的目标股价从12.00美元下调至10.00美元。

Get
获取
Lifecore Biomedical
生命科生物医学
alerts:
警报:

Lifecore Biomedical Trading Down 6.6 %

Lifecore 生物医学交易下跌6.6%

Shares of NASDAQ:LFCR opened at $3.04 on Monday. Lifecore Biomedical has a fifty-two week low of $1.52 and a fifty-two week high of $11.95. The stock has a 50-day simple moving average of $5.80. The stock has a market cap of $92.17 million, a price-to-earnings ratio of -1.22 and a beta of 1.11.

纳斯达克股票代码:LFCR的股价周一开盘价为3.04美元。Lifecore Biomedical创下五十二周低点1.52美元,五十二周高点为11.95美元。该股的50天简单移动平均线为5.80美元。该股的市值为9,217万美元,市盈率为-1.22,beta值为1.11。

About Lifecore Biomedical

关于 Lifecore B

(Get Rating)

(获取评分)

Lifecore Biomedical, Inc engages in the design, development, manufacture, and sale of health and wellness products for food and biomaterials markets. It operates through the following segments: Lifecore, Curation Foods, and Others. The Lifecore segment sells products utilizing hyaluronan, a naturally occurring polysaccharide that is widely distributed in the extracellular matrix of connective tissues in both animals and humans.

Lifecore Biomedical, Inc从事食品和生物材料市场健康和保健产品的设计、开发、制造和销售。它通过以下部门运营:Lifecore、Curation Foods等。Lifecore 部门销售利用透明质酸的产品,透明质酸是一种天然存在的多糖,广泛分布在动物和人类结缔组织的细胞外基质中。

Read More

阅读更多

  • Get a free copy of the StockNews.com research report on Lifecore Biomedical (LFCR)
  • KB Home Strong Results Lift Prices
  • Chewy Stock Is Setting Up For Long-Term Profitable Growth
  • Why Wall Street Loves These 3 Penny Stocks
  • Low Volume Bunge Plunge Presents an Opportunity
  • Carvana May Be Able To Reach Profitability This Year
  • 免费获取 StockNews.com 关于 Lifecore Biomedical (LFCR) 的研究报告
  • KB Home 强劲业绩提振了价格
  • Chewy Stock 正在为长期盈利增长做准备
  • 为什么华尔街喜欢这三只细价股
  • 低音量蹦极跳提供了机会
  • Carvana 今年可能能够实现盈利

Receive News & Ratings for Lifecore Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lifecore Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.

接收 Lifecore 生物医学日报的新闻和评级 -在下面输入您的电子邮件地址,即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Lifecore Biomedicare及相关公司的最新新闻和分析师评级的简明每日摘要。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发